DUBLIN, March 13, 2014 /PRNewswire/ --
Research and Markets (http://www.researchandmarkets.com/research/43nvqj/cancer_monoclonal) has announced the addition of the "Cancer Monoclonal Antibodies Market Forecast to 2017" report to their offering.
Cancer, one of the leading causes of death worldwide, affected approximately 13 Million people in 2012 and this figure is expected to grow to 17 Million by 2020. The dramatic increase in the size of the potential cancer market has prompted pharmaceutical players to invest in the oncology sector with major focus on monoclonal antibodies.
Monoclonal antibodies identify cancer cells, bind to proteins on their surface, and stimulate an immune response so are very specific to targets. Various monoclonal antibodies for treatment of cancer are available in the market and many more are in the pipeline. According to this report, "Cancer Monoclonal Antibodies Market Forecast to 2017", the market for cancer mAbs is estimated at US$ 24 Billion, and is expected to grow to around US$ 34 Billion by 2017.
The report, in particular, provides an insight to the global burden of cancer, with detailed breakdown of incidences by type and geography. It not only estimates the current burden but also makes future predictions. There is an exhaustive overview of the monoclonal technology, helping the client understand the various types of antibodies and the diverse types of cancer therapies which make use of mAbs.
In this report, the authors have profiled every anti-cancer monoclonal antibody available in the market and estimated the current and future market of five of them. The report covers major trends which are driving the current market and a country level analysis of the status of cancer mAbs.
Through this pipeline analysis of the various mAbs, it has been revealed that majority of the mAbs in the pipeline are in phase III trials with most of them devoted to Solid Tumor, Lung Cancer, Breast Cancer, and NHL. The approval of these drugs will drive a major change in the market in terms of market share of current drugs.
Finally, the authors conclude its report with a competitive analysis of the major mAb players, providing brief descriptions of every player along with a list of current and pipeline mAbs. The report can therefore, provide assistance in evaluating the current market, discovering potential areas and analyzing the competitive environment.
Key Topics Covered:
1. Analyst View
2. Research Methodology
3. The Global Burden of Cancer
4. Global Cancer Market Outlook to 2017
5. Monoclonal Antibodies: Introduction and Working
6. Industry Trends and Drivers
7. Global Cancer mAbs Market Outlook to 2017
8. Pipeline Analysis of Cancer Monoclonal Antibodies
9. Competitive Landscape
- Bristol-Myers Squibb
- Eli Lilly
- Seattle Genetics
- Spectrum Pharmaceuticals
For more information visit http://www.researchandmarkets.com/research/43nvqj/cancer_monoclonal
Media Contact: Laura Wood , +353-1-481-1716, email@example.com
SOURCE Research and Markets